Related Experiment Video

Updated: Aug 21, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention

Margie L Clapper1, Jacques Coudry, Wen-Chi L Chang

  • 1Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. margie.clapper@fccc.edu

Mutation Research
|October 13, 2004
PubMed

Insights

Targeting Wnt signaling by disrupting beta-catenin-mediated TCF signaling shows promise for preventing intestinal tumors. Several agents modulate beta-catenin, offering potential chemopreventive strategies for cancer intervention.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Chemoprevention

Background:

  • Wnt signaling pathway dysregulation is implicated in intestinal tumor formation and other cancers.
  • Targeting beta-catenin-mediated TCF signaling is a potential strategy for cancer chemoprevention.
  • Preclinical studies suggest agents can inhibit TCF signaling and modulate beta-catenin localization.

Purpose of the Study:

  • To explore the potential of disrupting beta-catenin-mediated TCF signaling for intestinal cancer chemoprevention.
  • To review current understanding of agents affecting TCF signaling and beta-catenin.
  • To discuss mechanisms by which agents may inhibit Wnt signaling.

Main Methods:

  • Review of preclinical data on agents affecting TCF-4 regulatory elements (pTOPFLASH).
  • Analysis of studies demonstrating modulation of beta-catenin subcellular localization by agents like sulindac.
  • Discussion of proposed mechanisms for disrupting beta-catenin-mediated TCF signaling.

Main Results:

  • Several synthetic and natural agents decrease TCF-4 transcriptional activity.
  • Agents such as sulindac, sulindac sulfone, and indomethacin alter beta-catenin's subcellular localization in vivo.
  • Potential mechanisms include inhibiting complex formation, enhancing degradation, accelerating nuclear export, or increasing E-cadherin sequestration.

Conclusions:

  • Disrupting beta-catenin-mediated TCF signaling is a promising chemopreventive strategy for intestinal tumors.
  • Further elucidation of mechanisms is needed, but agents show potential for cancer intervention.
  • The dual role of beta-catenin in Wnt signaling and cell adhesion offers opportunities for comprehensive cancer therapies.

Related Concept Videos

Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...